Proliferative Diabetic Retinopathy (PDR) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Proliferative Diabetic Retinopathy (PDR) – Drugs In Development, 2024 report and make more profitable business decisions.
Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. PDR occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue, causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision, and difficulty with color perception.
The Proliferative Diabetic Retinopathy (PDR) drugs in development market research report provide comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Proliferative Diabetic Retinopathy (PDR) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Proliferative Diabetic Retinopathy (PDR) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Proliferative Diabetic Retinopathy (PDR) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Proliferative Diabetic Retinopathy (PDR) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Boehringer Ingelheim International GmbHDaegu Gyeongbuk Medical Innovation Foundation
Kubota Vision Inc
Novartis AG
Ocuphire Pharma Inc
OcuTerra Therapeutics Inc
Ribomic Inc
Valo Health LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Proliferative Diabetic Retinopathy (PDR) reports